Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Jan;84(1):81–91.

A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit.

A M Breckenridge, S Cholerton, J A Hart, B K Park, A K Scott
PMCID: PMC1987219  PMID: 3978316

Abstract

The pharmacokinetics and pharmacodynamics of the 4-hydroxycoumarin anticoagulants, brodifacoum, difenacoum, and warfarin have been studied in the rabbit. Sensitive (50 ng ml-1) and specific high performance liquid chromatography assays have been developed for the determination of plasma concentrations of warfarin, brodifacoum and difenacoum. After administration of a single intravenous dose (20 mumol kg-1), plasma concentrations of warfarin underwent mono-exponential decay, with a terminal half-life of 5.6 +/- 0.7 h (mean +/- s.e. mean), whereas plasma concentrations of brodifacoum and difenacoum underwent bi-exponential decay with terminal half-lives of 60.8 +/- 1.9 h and 83.1 +/- 10.3 h respectively. The plasma half-life of brodifacoum in a single patient poisoned with the compound was 487 h. The pharmacological response to the anticoagulants was measured as changes in prothrombin complex activity, from which the rate of clotting factor synthesis was determined. Clotting factor synthesis recovered in a monophasic fashion after a single intravenous dose of warfarin, compared with a more complex biphasic, pattern of recovery of clotting factor synthesis after administration of either brodifacoum or difenacoum. The slope (m) of the intensity of effect-log (amount of drug in the body) curve was derived for each anticoagulant. There was no significant difference in the value of m after single intravenous doses of racemic, R-, and S-warfarin, difenacoum and brodifacoum, which is consistent with the hypothesis that all the 4-hydroxycoumarin anticoagulants produce their anticoagulant effect by acting at the same receptor site, vitamin K epoxide reductase. Determination of the minimum plasma concentration of each anticoagulant that corresponded with the complete inhibition of clotting factor synthesis indicated that racemic warfarin, R-warfarin and brodifacoum have similar potencies in the rabbit and are less potent than S-warfarin and difenacoum.

Full text

PDF
81

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggeler P. M., O'Reilly R. A. The pharmacological basis of oral anticoagulant therapy. Thromb Diath Haemorrh Suppl. 1966;21:227–256. [PubMed] [Google Scholar]
  2. Bachmann K. A., Sullivan T. J. Dispositional and pharmacodynamic characteristics of brodifacoum in warfarin-sensitive rats. Pharmacology. 1983;27(5):281–288. doi: 10.1159/000137881. [DOI] [PubMed] [Google Scholar]
  3. Barlow A. M., Gay A. L., Park B. K. Difenacoum (Neosorexa) poisoning. Br Med J (Clin Res Ed) 1982 Aug 21;285(6341):541–541. doi: 10.1136/bmj.285.6341.541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bell R. G., Matschiner J. T. Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature. 1972 May 5;237(5349):32–33. doi: 10.1038/237032a0. [DOI] [PubMed] [Google Scholar]
  5. Bell R. G. Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K--epoxide cycle. Fed Proc. 1978 Oct;37(12):2599–2604. [PubMed] [Google Scholar]
  6. Breckenridge A., Orme M. L., Davies L., Thorgeirsson S. S., Davies D. S. Dose-dependent enzyme induction. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):514–520. doi: 10.1002/cpt1973144part1514. [DOI] [PubMed] [Google Scholar]
  7. Breckenridge A., Orme M. L. The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats. Life Sci II. 1972 Apr 8;11(7):337–345. doi: 10.1016/0024-3205(72)90073-2. [DOI] [PubMed] [Google Scholar]
  8. Breckenridge A., Orme M., Wesseling H., Lewis R. J., Gibbons R. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther. 1974 Apr;15(4):424–430. doi: 10.1002/cpt1974154424. [DOI] [PubMed] [Google Scholar]
  9. Covell D. G., Abbrecht P. H., Berman M. The effect of hepatic uptake on the disappearance of warfarin from the plasma of rats: a kinetic analysis. J Pharmacokinet Biopharm. 1983 Apr;11(2):127–145. doi: 10.1007/BF01061845. [DOI] [PubMed] [Google Scholar]
  10. Hadler M. R., Shadbolt R. S. Novel 4-hydroxycoumarin anticoagulants active against resistant rats. Nature. 1975 Jan 24;253(5489):275–277. doi: 10.1038/253275a0. [DOI] [PubMed] [Google Scholar]
  11. Jackson C. M., Suttie J. W. Recent developments in understanding the mechanism of vitamin K and vitamin K-antagonist drug action and the consequences of vitamin K action in blood coagulation. Prog Hematol. 1977;10:333–359. [PubMed] [Google Scholar]
  12. Koubek K. G., Ussary J. P., Haulsee R. E. High pressure liquid chromatographic determination of the rodenticide brodifacoum in rat tissue. J Assoc Off Anal Chem. 1979 Nov;62(6):1297–1301. [PubMed] [Google Scholar]
  13. Leck J. B., Park B. K. A comparative study of the effects of warfarin and brodifacoum on the relationship between vitamin K1 metabolism and clotting factor activity in warfarin-susceptible and warfarin-resistant rats. Biochem Pharmacol. 1981 Jan 15;30(2):123–128. doi: 10.1016/0006-2952(81)90182-9. [DOI] [PubMed] [Google Scholar]
  14. Nagashima R., O'Reilly R. A., Levy G. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther. 1969 Jan-Feb;10(1):22–35. doi: 10.1002/cpt196910122. [DOI] [PubMed] [Google Scholar]
  15. Nielsen-Kudsk F. A pharmacokinetic program for TI-59. J Pharmacol Methods. 1980 Jun;3(4):345–355. doi: 10.1016/0160-5402(80)90076-5. [DOI] [PubMed] [Google Scholar]
  16. O'REILLY R. A., AGGELER P. M., LEONG L. S. STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. J Clin Invest. 1963 Oct;42:1542–1551. doi: 10.1172/JCI104839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Park B. K., Leck J. B. A comparison of vitamin K antagonism by warfarin, difenacoum and brodifacoum in the rabbit. Biochem Pharmacol. 1982 Nov 15;31(22):3635–3639. doi: 10.1016/0006-2952(82)90587-1. [DOI] [PubMed] [Google Scholar]
  18. Park B. K., Leck J. B., Wilson A. C., Serlin M. J., Breckenridge A. M. A study of the effect of anticoagulants on [3H]vitamin K1 metabolism and prothrombin complex activity in the rabbit. Biochem Pharmacol. 1979 Apr 15;28(8):1323–1329. doi: 10.1016/0006-2952(79)90433-7. [DOI] [PubMed] [Google Scholar]
  19. Takada K., Levy G. Comparative pharmacokinetics of coumarin anticoagulants XLIII: Concentration-dependent hepatic uptake of warfarin in rats. J Pharm Sci. 1979 Dec;68(12):1569–1571. doi: 10.1002/jps.2600681233. [DOI] [PubMed] [Google Scholar]
  20. Wilson A. C., Park B. K. The effect of phenobarbitone pre-treatment on vitamin K1 disposition in the rat and rabbit. Biochem Pharmacol. 1984 Jan 1;33(1):141–146. doi: 10.1016/0006-2952(84)90381-2. [DOI] [PubMed] [Google Scholar]
  21. Wingard L. B., Jr, O'Reilly R. A., Levy G. Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations. Clin Pharmacol Ther. 1978 Feb;23(2):212–217. doi: 10.1002/cpt1978232212. [DOI] [PubMed] [Google Scholar]
  22. Yacobi A., Wingard L. B., Jr, Levy G. Comparative pharmacokinetics of coumarin anticoagulants. X. Relationship between distribution, elimination, and anticoagulant action of warfarin. J Pharm Sci. 1974 Jun;63(6):868–872. doi: 10.1002/jps.2600630613. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES